Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9346450 | Ophthalmology | 2005 | 10 Pages |
Abstract
Dorzolamide reduced IOP by 15% to 22% throughout the 5 years of the trial. However, the EGPS failed to detect a statistically significant difference between medical therapy and placebo in reducing the incidence of POAG among a large population of OHT patients at moderate risk for developing POAG, because placebo also significantly and consistently lowered IOP.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
The European Glaucoma Prevention Study (EGPS) Group The European Glaucoma Prevention Study (EGPS) Group,